Riskpilot← Back to searchSign inGet full accessSL.Pharma Oy
OYActiveY-tunnus 3085704-8Ulvilantie 10-B9Other human health activities n.e.c. · NACE 8699Est. 2019— employees
Revenue 2025
EUR 1,3M
+8% vs 2024
EBITDA margin
27.1%
-84% vs 2024
Equity ratio
93.3%
Financial strength
Net profit 2025
EUR 263K
+16% vs 2024
| Revenue | EUR 1,3M | +8% |
| EBITDA | EUR 359K | -84% |
| Net profit | EUR 263K | +16% |
| Total assets | EUR 1,1M | +20% |
| Equity | EUR 1,1M | +22% |
| Employees | — | — |
Legal name
SL.Pharma Oy
Y-tunnus number
3085704-8
Legal form
Osakeyhtiö
NACE code
8699 · Other human health activities n.e.c.
Founded
9. syyskuuta 2019
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Company purpose
Yhtiön toimiala on terveystuotteiden, lääkkeiden käyttöön tarvittavien välineiden ja tarvikkeiden, nikotiinivalmisteiden, luontaistuotteiden, elintarvikkeiden ja kosmeettisten valmisteiden ja muiden ns. vapaankaupan tuotteiden vähittäiskauppa, tukkukauppa, valmistus, maahantuonti ja maastavienti. Yhtiön toimialaan kuuluvat myös lääkehoidon tukipalvelut, kosmetologin palvelut, konsultointi- ja koulutuspalvelut, kuljetuspalvelut ja henkilöstönvuokraus. Lisäksi yhtiön toimialaan kuuluvat kiinteistöjen ja maa-alueiden, osuuksien, osakkeiden ja muiden arvopapereiden ostaminen, hallitseminen ja myyminen.
Address
Ulvilantie 10-B9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1 014 | 1 409 | 1 200 | 1 200 | 1 226 | 1 323 |
| Staff expenses | — | −0 | 0 | 0 | 0 | −0 |
| EBITDA | 218 | 319 | 2 179 | 2 169 | 2 217 | 359 |
| Depreciation & amort. | — | −13 | 46 | 34 | 37 | −28 |
| EBIT | 218 | 305 | 209 | 263 | 291 | 331 |
| Net financials | −0 | −0 | 0 | 2 | −2 | 1 |
| Profit before tax | 218 | 305 | 210 | 266 | 285 | 329 |
| Tax | 44 | 61 | 42 | 54 | 58 | −66 |
| Net profit | 174 | 244 | 168 | 212 | 227 | 263 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 216 | 543 | 621 | 755 | 956 | 1 149 |
| Equity | 174 | 404 | 540 | 708 | 879 | 1 072 |
| Long-term debt | — | 6 | 0 | — | — | — |
| Short-term debt | 41 | 133 | 82 | 46 | 78 | 77 |
| Total debt | 41 | 139 | 82 | 46 | 78 | 77 |
EBITDA margin
27.1%
This company
15.8%
Market median
+72% vs market
20202025
Equity ratio
93.3%
This company
38.2%
Market median
+144% vs market
20202025
Return on equity
24.6%
This company
18.4%
Market median
+34% vs market
20202025
Net profit margin
19.9%
This company
8.1%
Market median
+146% vs market
20202025
Asset turnover
1.15×
This company
1.12×
Market median
+3% vs market
20202025
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20202025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2019-09-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
JB Audit | Audit | 2019 | — | — |
RE Deputy Member | Deputy Member | 2019 | — | — |
TT Deputy auditor | Deputy auditor | 2019 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SL.Pharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Margareta Susanne Lindberg | Chief Executive Officer | 0 companies |
| Jan-Erik Björklöf | Audit | 0 companies |
| Rasmus Elias Vähä-Soini | Deputy Member | 0 companies |
| Timo Tapio Post | Deputy auditor | 0 companies |